Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Jenkins, Helen E ^a,b   Zignol, Matteo ^c   Cohen, Ted ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

AFRICA; ARTICLE; EUROPEAN UNION; GEOGRAPHY; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; PREVALENCE; SEROPREVALENCE; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; ADULT; COMORBIDITY; DIRECTLY OBSERVED THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; PATHOGENICITY; TIME; TUBERCULOSIS; VIROLOGY;

ADULT; ANTITUBERCULAR AGENTS; COMORBIDITY; DIRECTLY OBSERVED THERAPY; HIV; HIV INFECTIONS; HUMANS; INCIDENCE; ISONIAZID; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 79960904886     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022927     Document Type: Article

References (29)

1. World Health Organization (2010) Global Tuberculosis Control 2010. Geneva Stop TB Department. WHO Press WHO/HTM/TB/2010. 7. Available: http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf. ISBN: 978 92 4 156406 9.
2. World Health Organization (2010) Multidrug and extensively drug-resistant (M/XDR-TB). 2010 Global Report on Surveillance and Response. Geneva WHO Press WHO/HTM/TB/2010. 3. Available: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. ISBN: 978 92 4 159919 1.
3. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, et al. (2000) A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45: 859-870.
4. Hafner R, Cohn JA, Wright DJ, Dunlap NE, Egorin MJ, et al. (1997) Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group. Am J Respir Crit Care Med 156: 918-923.
5. Rieder H, (2002) Interventions for Tuberculosis Control and Elimination. Paris International Union Against Tuberculosis and Lung Disease.
6. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, et al. (2009) Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 6: e1000150.
7. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, et al. (2009) Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 6: e1000146.
8. Akolo C, Adetifa I, Shepperd S, Volmink J, (2010) Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev.
9. World Health Organisation (2010) Guidelines for intensified case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva Stop TB Department and Department of HIV/AIDS Available: http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf. ISBN: 978 92 4 150070 8.
10. World Health Organization (2009) Guidelines for drug resistance surveillance in tuberculosis, 4th edition. Geneva WHO Press WHO/HTM/TB/2009.422. Available: http://whqlibdoc.who.int/publications/2009/9789241598675_eng.pdf. ISBN: 978 92 4 159867 5.
11. World Health Organization (1997) Anti-tuberculosis drug resistance in the world, report no. 1. Geneva WHO Press WHO/TB/97.229. Available: http://whqlibdoc.who.int/hq/1997/WHO_TB_97.229.pdf.
12. World Health Organization (2000) Anti-tuberculosis drug resistance in the world, report no. 2. Geneva WHO Press WHO/CDS/TB/2000.278. Available: http://whqlibdoc.who.int/hq/2000/WHO_CDS_TB_2000.278_intro.pdf.
13. World Health Organization (2004) Anti-tuberculosis drug resistance in the world, report no. 3. Geneva WHO Press WHO/HTM/TB/2004.343. Available: http://www.who.int/tb/publications/who_htm_tb_2004_343/en/index.html. ISBN: 92 4 156285 4.
14. World Health Organization (2008) Anti-tuberculosis drug resistance in the world, report no. 4. Geneva WHO Press WHO/HTM/TB/2008.394. Available: http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.394_eng.pdf.
15. UNAIDS, (2010) UNAIDS Report on the Global AIDS Epidemic 2010. UNAIDS/10.11E{pipe}JC1958E. Available: http://www.unaids.org/globalreport/Global_report.htm. ISBN: 978 92 9173 871 7.
16. Dye C, Lonnroth K, Jaramillo E, Williams BG, Raviglione M, (2009) Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 87: 683-691.
17. Lew W, Pai M, Oxlade O, Martin D, Menzies D, (2008) Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149: 123-134.
18. Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N, (2008) Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis 14: 1345-1352.
19. Samandari T, Mosimaneotsile B, Agizew T, Nyirenda S, Tedla Z, et al. (2009) Preliminary results of the Botswana Isoniazid Preventive Therapy (IPT) clinical trial (6 months vs 36 months). Cancun, Mexico 40th Union World Lung Conference.
20. Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, et al. (2010) Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. J Acquir Immune Defic Syndr 54: 71-77.
21. Basu S, Maru D, Poolman E, Galvani A, (2009) Primary and secondary tuberculosis preventive treatment in HIV clinics: simulating alternative strategies. Int J Tuberc Lung Dis 13: 652-658.
22. Leimane V, Leimans J, (2006) Tuberculosis control in Latvia: integrated DOTS and DOTS-plus programmes. Euro Surveill 11: 29-33.
23. Falzon D, van Cauteren D, (2008) Demographic features and trends in tuberculosis cases in the European Region, 1995-2005. Euro Surveill 13.
24. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, et al. (2006) Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368: 2142-2154.
25. World Health Organization Portugal: Tuberculosis (TB) screening and drug addiction.
26. Abebe G, Paasch F, Apers L, Rigouts L, Colebunders R, (2011) Tuberculosis drug resistance testing by molecular methods: opportunities and challenges in resource limited settings. J Microbiol Methods 84: 155-160.
27. Ling DI, Zwerling AA, Pai M, (2008) GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32: 1165-1174.
28. Helb D, Jones M, Story E, Boehme C, Wallace E, et al. (2010) Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48: 229-237.
29. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F, (2000) Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis 4: 481-484.